20/20 BioLabs announced an investor webinar on August 5, 2026, where CEO Jonathan Cohen will discuss the company's recent business development tour in East Asia, including participation in BIO Asia-Taiwan and meetings in Taipei, Tokyo, and Seoul. The webinar will cover the company's strategy for mergers, acquisitions, and partnerships in the region, emphasizing East Asia's importance for cancer screening and health-check programs. The company aims to leverage these relationships to support its technology platform and accelerate commercialization of its AI-powered blood tests. Attendees will also receive a promotional discount for the OneTest product line.
Crescent Biopharma announced its second quarter 2026 financial results, highlighting progress in clinical trials for its cancer therapies, including CR-001, a PD-1 x VEGF bispecific antibody, and ADC candidates CR-002 and CR-003. The company is enrol...
Ferrari reported Q2 2026 net revenues of €1.94 billion, up 8% year-on-year, driven by a richer product mix and increased personalization sales. Operating profit rose 10% to €605 million with a margin of 31.2%, while net profit grew 9% to €463 million...
Dimensional Fund Advisors Ltd. has publicly disclosed holding a 1.58% stake in Gamma Communications PLC as of July 29, 2026. The disclosure, made under Rule 8.3 of the Takeover Code, indicates ownership of 1,414,785 ordinary shares. This filing is a ...
Injective, a layer-1 blockchain focused on financial applications, has reduced its block times to 0.59 seconds following a mainnet upgrade. This improvement nearly halves transaction finality time since April, enhancing speed critical for derivatives...
High-yield savings accounts (HYSAs) offer better interest rates than typical savings accounts, making them ideal for emergency funds. However, they are not suitable if you carry credit card debt, as the interest on debt far exceeds HYSA earnings. Als...
